Get the latest news, insights, and market updates on DNA (Ginkgo Bioworks Holdings, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
How Recent Developments Are Shaping the Ginkgo Bioworks Investment Story
Ginkgo Bioworks Holdings has recently seen its fair value price target reaffirmed at $12.00 per share. The discount rate has increased from 8.53% to 9.26% to account for a slightly higher risk profile. Analysts note that while revenue growth forecasts remain stable at about 5.22%, the outlook is shaped by both positive short-term developments and caution over long-term uncertainties. Stay tuned to discover how investors can track these evolving narratives and stay informed about future... Nov 9, 2025 - $DNA
Ginkgo Bioworks Reports Third Quarter 2025 Financial Results
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the third quarter ended September 30, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com. Nov 6, 2025 - $DNA
Ginkgo Bioworks Awarded Project Agreement through BARDA's BioMaP-Consortium
Ginkgo Bioworks (NYSE: DNA) announced today that it has been awarded a contract through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to develop innovations that strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies (mAbs) to protect against and treat infection by filoviruses such as Ebola (EBOV) and Sudan Viruses (SUDV). Nov 3, 2025 - $DNA
Ginkgo Bioworks and Bayer Extend Multi-Year Strategic Partnership to Accelerate Next Generation Biological Solutions for Agriculture
Ginkgo Bioworks (NYSE: DNA) today announced that the company has extended its multi-year strategic partnership with Bayer to advance research and development of biological products for agriculture. With the extension of this partnership, which began in 2017, both parties will build on the success of their ongoing collaboration to develop innovative microbial nitrogen fixation. As with the original agreement, Bayer retains the right to commercialize the resulting biological products as a compleme Oct 31, 2025 - $DNA
Ginkgo Bioworks Announces Date of Third Quarter 2025 Results Presentation
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, beginning at 4:30 p.m. ET. Oct 30, 2025 - $DNA
Why Analysts Are Divided on Ginkgo Bioworks as Its Story Shifts with New Developments
Ginkgo Bioworks Holdings has maintained its fair value price target at $12.00 per share, with only slight shifts in the underlying assessment from market analysts. The minor increase in the discount rate reflects a careful balancing of optimism about the company’s recent revenue outperformance and cost efficiency efforts, while also considering ongoing uncertainties in its growth outlook. Stay tuned to discover how you can keep track of future updates to Ginkgo Bioworks’ investment narrative... Oct 24, 2025 - $DNA
Ginkgo Bioworks in Partnership with STRM.BIO and University of British Columbia in Project to Develop In Vivo CAR Therapies Under ARPA-H's EMBODY Program
Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with STRM.BIO and the University of British Columbia (UBC) as part of the Advanced Research Projects Agency for Health's (ARPA-H) Engineering of Immune Cell Inside the Body (EMBODY) program. EMBODY is led by ARPA-H Program Manager Daria Fedyukina, Ph.D. The partnership aims to develop in vivo chimeric antigen receptor (CAR) therapies for autoimmune diseases, leveraging Ginkgo's expertise in RNA construct design and immune cell engineeri Oct 23, 2025 - $DNA
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple